KCT0007066
Not yet recruiting
未知
Evaluation pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanil in patients underwent surgery
ConditionsNot Applicable
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not Applicable
- Sponsor
- Inje University Busan Paik Hospital
- Enrollment
- 15
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •the patients who undergoing general anesthesia during regular surgery at Busan Paik Hospital, aged 18 to 85 and rated 1 to 3 class by the American Society of Anesthesia classification
Exclusion Criteria
- •Patients with difficulty in communication, hypersensitivity to benzodiazepine or flumagenyl, neurological disorders (such as cognitive impairment, dementia etc.) that may affect cognitive function, past history within three months or current use of drugs that affect the central nervous system (such as antipsychotics, antidepressants, anti\-anxiety drugs, anticonvulsants, etc.), alcohol addiction within two years, a history of alcohol dependence
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Assessment of pharmacokinetics and pharmacokinetic drug-drug interaction with ketoconazole of the metabolite S 41015 after single oral unlabelled microdoses of S 41015 and i.v. radiolabelled microdoses of [14C]-S 41015, and pharmacokinetics of S 38844 after single oral unlabelled microdose of S 38844 and i.v. radiolabelled microdose of [14C]-S 38844 in healthy male participantshart- en vaatziektencardiovascular diseasesNL-OMON38625Institut de Recherches Internationales Servier I.R.I.S6
Active, not recruiting
Not Applicable
Evaluation of blood drug level profile, effect and safety after repeated administration of a slow release formulation of S-38844 in healthy male volunteersEUCTR2010-020197-42-DEInstitut de Recherches Internationales Servier27
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).Patients with chronic heart failure and left ventricular systolicdysfunctionMedDRA version: 17.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2013-003000-39-BEInstitut de Recherches Internationales Servier125